- Home
- BHAT vs XFOR Comparison
BHAT vs XFOR Comparison
Compare BHAT & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHAT
- XFOR
- Stock Information
- Founded
- BHAT 2010
- XFOR 2014
- Country
- BHAT China
- XFOR United States
- Employees
- BHAT N/A
- XFOR N/A
- Industry
- BHAT Recreational Games/Products/Toys
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BHAT Consumer Discretionary
- XFOR Health Care
- Exchange
- BHAT Nasdaq
- XFOR Nasdaq
- Market Cap
- BHAT 12.7M
- XFOR 11.3M
- IPO Year
- BHAT 2019
- XFOR N/A
- Fundamental
- Price
- BHAT $1.67
- XFOR $1.42
- Analyst Decision
- BHAT
- XFOR Strong Buy
- Analyst Count
- BHAT 0
- XFOR 3
- Target Price
- BHAT N/A
- XFOR $72.33
- AVG Volume (30 Days)
- BHAT 85.4K
- XFOR 1.9M
- Earning Date
- BHAT 04-30-2025
- XFOR 08-19-2025
- Dividend Yield
- BHAT N/A
- XFOR N/A
- EPS Growth
- BHAT N/A
- XFOR N/A
- EPS
- BHAT N/A
- XFOR N/A
- Revenue
- BHAT $18,724,190.00
- XFOR $32,774,000.00
- Revenue This Year
- BHAT N/A
- XFOR $1,300.08
- Revenue Next Year
- BHAT N/A
- XFOR N/A
- P/E Ratio
- BHAT N/A
- XFOR N/A
- Revenue Growth
- BHAT N/A
- XFOR 5721.31
- 52 Week Low
- BHAT $1.61
- XFOR $1.35
- 52 Week High
- BHAT $72.80
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- BHAT 38.80
- XFOR 36.14
- Support Level
- BHAT $1.75
- XFOR $1.54
- Resistance Level
- BHAT $1.79
- XFOR $1.73
- Average True Range (ATR)
- BHAT 0.09
- XFOR 0.21
- MACD
- BHAT -0.01
- XFOR 0.02
- Stochastic Oscillator
- BHAT 9.27
- XFOR 7.78
About BHAT Blue Hat Interactive Entertainment Technology
Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.